about
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neckA prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.Impact of organised programs on colorectal cancer screening.Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck.Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma]New advances in DPYD genotype and risk of severe toxicity under capecitabine.The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after studyImpact of glycosylation on the effect of cytokines. A special focus on oncology.Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyIn the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Efficacy of trabectedin in metastatic solitary fibrous tumor.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyAdjuvant chemotherapy for primary cardiac sarcomas: the IGR experienceCost-utility analyses of drug therapies in breast cancer: a systematic review.Molecularly targeted agents: their promise as cancer chemopreventive interventions.Cancer screening in France: subjects' and physicians' attitudesA multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracilMaintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancerA time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.Efficacy and safety of ixabepilone, a novel epothilone analogue.A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.Ixabepilone: a new active chemotherapy in the treatment of breast cancer.Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.Response rates: a valuable signal of promising activity?Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.Safety profile of new anticancer drugs.Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
P50
Q28347912-FC4FEFA8-CE46-46D5-BEE2-EC79E33A7415Q30317232-6D23C5D0-E942-4BB2-B819-8F3DD0879D68Q31959172-D62850E9-E97E-43CE-9752-792307845F91Q31992287-457E7E1D-4AC3-475A-B1FF-C6D53DC43958Q33328300-4F948A02-279C-4592-8612-A8C6670C6013Q33335641-B1072FFD-24AF-4904-8B9F-DAAFE5E1D791Q33391954-B1EC7A9B-F89A-485D-926B-C00D32E5CD22Q33417019-56F00AA3-3F9E-4FF3-82AB-A03B5D58D76BQ33489008-BDAD29FB-3E86-4CD3-A116-0FB3BC9C6109Q33648195-F18091D4-4F2C-4A61-8B7A-8E29BB9875B4Q33685213-F60D962F-8AEA-41B3-A6A8-A225A37684ACQ33777431-BDC2A37D-B1C3-4653-B152-062CD557B91EQ33823991-EC20A292-D880-44CF-B3A0-2029C2A2630FQ34000716-577CE07B-B959-4E36-99C1-DBFEDC1143C3Q34723777-C605F85C-2C20-44B0-A8F1-B9E0E2944AEDQ34982545-C0861749-2E8F-4CF6-B98D-76D6CE3530F5Q35114038-A117E3D6-23D1-452F-A92E-6CDD1359C2D9Q35345516-933E0C10-EEEA-4C22-8611-6F76EC11B613Q35526830-7AFC6075-A82A-4A2D-8A3A-BFCF97D44FDAQ35915708-C64A6010-96A5-48F3-8A2E-4432084BD0BFQ36115838-00A90762-CD45-48FC-B161-3F1A1F4FCD9EQ36116276-03221C87-9CF3-4074-BA6C-D4A165814EDFQ36228569-F95AF2B3-F41F-4711-B34B-AC56E2A58FB5Q36570120-9C5D848F-6FF1-47DD-B95E-0234098116C0Q36619294-C9DFB186-79BA-492C-ADF1-0CC9FD8B41FCQ36632687-1B0BF33B-EAC3-4F71-8AA6-9AF69152DBB9Q36706854-78C7D265-9567-4BC9-B3F7-5811FD32D415Q36746794-74318565-64D7-4214-BB64-1186EC44D6C7Q36825132-17F35CE4-6E97-4D83-956E-E9AD3073465DQ36892821-6924B9FA-3E85-4023-8AAD-8595620A3510Q37123925-8495E7A6-E115-4A3C-B40A-6B45B9E89131Q37131988-D4F20898-D837-43BE-A364-07DA05112282Q37187292-D4FDF865-C49B-4DB4-9ED7-4191C65CE75FQ37401833-2BB6A8D4-5E4E-43B6-B418-109003F333BFQ37580439-22C01FFA-828C-4F4A-918E-EF252380BB83Q37614162-575113E7-BA20-4DDB-A522-224AA4EAC28FQ37616807-FD8E0E4D-8E1D-4090-95BE-AB05BA3379E5Q37696502-B0854945-0B5C-4186-B62A-A9E1CA885D1DQ37718401-4A63C6D5-9187-42D4-98C0-B84E2017D2DBQ38077764-92252790-D659-4F86-AF1E-69512C198295
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Xavier Pivot
@ast
Xavier Pivot
@en
Xavier Pivot
@es
Xavier Pivot
@nl
type
label
Xavier Pivot
@ast
Xavier Pivot
@en
Xavier Pivot
@es
Xavier Pivot
@nl
prefLabel
Xavier Pivot
@ast
Xavier Pivot
@en
Xavier Pivot
@es
Xavier Pivot
@nl
P31
P496
0000-0003-3689-5013